Uniphar’s (UPR) “Buy” Rating Reiterated at Shore Capital

Uniphar (LON:UPRGet Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Shore Capital in a report issued on Tuesday,Digital Look reports.

Uniphar Stock Performance

Shares of LON:UPR traded up GBX 11.88 ($0.15) during trading on Tuesday, reaching GBX 212.88 ($2.69). 10,757 shares of the stock were exchanged, compared to its average volume of 30,248. Uniphar has a 12 month low of GBX 163 ($2.06) and a 12 month high of GBX 256 ($3.23). The firm has a market cap of £662.66 million, a PE ratio of 14.80 and a beta of 0.75. The stock has a 50-day moving average price of GBX 183.13 and a 200-day moving average price of GBX 197.29. The company has a current ratio of 0.90, a quick ratio of 0.60 and a debt-to-equity ratio of 119.48.

About Uniphar

(Get Free Report)

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

Featured Articles

Receive News & Ratings for Uniphar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniphar and related companies with MarketBeat.com's FREE daily email newsletter.